SOUTH PLAINFIELD, N.J.
Oct. 1, 2013
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Mr.
as Senior Vice President, Human Resources and Mr.
R.A. Session II
as Vice President, Corporate Development, both reporting to Ms.
, President of PTC Therapeutics, Inc. In addition, Dr.
has been promoted to Senior Vice President, Clinical Development.
"It is my pleasure to welcome Mr. Rexroad and Mr. Session to PTC as we expand the breadth of our management team. Mr. Rexroad's extensive experience will play an integral role in our ability to cultivate the human capital that enables our advancement as an organization and Mr. Session's experience in commercialization and finance will be an asset as we outline our strategy for growth," stated Ms.
, President, PTC Therapeutics, Inc. "In addition, we are delighted to announce the promotion of Dr.
. Since joining PTC, Dr. Barth has made significant contributions to the clinical development programs, corporate strategy and was an instrumental part of our recent IPO. Dr. Barth is an asset to our team and a cherished colleague."
Mr. Rexroad brings 25 years of experience across all areas of Human Resources in multiple industries and stages of development. Prior to joining PTC, Mr. Rexroad served as Vice President of Human Resources at Terumo Medical Corporation. From
, he served as Vice President of Human Resources at Osteotech, Inc. Prior to Osteotech, Mr. Rexroad held various positions in other industries including: New York Life Insurance Company and Altria Corporate Services, Inc. Mr. Rexroad received an M.S. in Business Administration focusing on Human Resources and Labor Relations and a B.S. in Business Management from
"I am delighted to join PTC at this exciting time in the company's history," stated Mr.
, Senior Vice President, Human Resources, PTC Therapeutics, Inc. "PTC is at a critical stage of its development, as a newly public company with lead product candidates in late-stage clinical trials. I look forward to being part of PTC's growth and development. The culture of innovation, collaboration and high scientific standards at PTC is parallel only to its commitments to patients and creates a remarkable work environment."
R.A. Session II
returns to PTC to work cross-functionally in corporate strategy, commercial development and finance. Prior to joining PTC, Mr. Session was Senior Director, Strategic Planning & Finance at Reata Pharmaceuticals where he led strategic analytics, valuation analysis, market access, pricing and long-range planning. Mr. Session was an integral part of the deal teams that successfully completed two of the largest licensing transactions in pharmaceutical history. Prior to Reata, Mr. Session served as Associate Director Strategic Planning & Finance at PTC from 2008 to 2010. Mr. Session has held various positions in strategic planning, drug development, and commercialization at other leading pharmaceutical companies including: AstraZeneca and Johnson & Johnson. He holds an MBA and MSF from
Texas A&M University at Commerce
, College of Business and Technology and a B.S. from the
University of North Carolina at Charlotte
, Belk College of Business.
leads PTC's clinical team and oversees all clinical trials at the company. Dr. Barth joined PTC in 2009 as Executive Director of Clinical Development. He was promoted to Vice President in 2011. Prior to joining PTC, Dr. Barth was Executive Director of Clinical Research at Merck from
, he served as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc. Dr. Barth received a B.A. from
and an M.D. from the
University of Pennsylvania
School of Medicine.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and are the basis for collaborations with leading biopharmaceutical companies. For more information, visit the company's web site at
Forward Looking Statements:
Any statements in this press release about future expectations, plans and prospects for the Company, the development of and potential market for the Company's product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" section of the final prospectus for our initial public offering, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.
SOURCE PTC Therapeutics, Inc.